In pre-clinical studies, miR-181b has been shown to promote cellular proliferation and reduce apoptosis in cervical cancer cells[32], mediate tumorigenesis through STAT3[33], and induce gemcitabine resistance in pancreatic cancer cells[34]. This evidence concerns the gene STAT3 and pancreatic neoplasm.